Phyteau, Inc.

Phyteau, Inc. is a biotechnology startup making strides in the realm of incretin therapy for diabetes, obesity, NAFLD, and related metabolic conditions. Through their innovative approach, the company targets the intestines to effectively enhance the levels of crucial metabolic hormones such as GLP-1, PYY, and CCK. This triggers a natural and potent control over blood sugar, appetite, food intake, and metabolism. Phyteau's technology, originating from leading institutions including UCLA, Caltech, and Cedars Sinai Medical Center, has the potential to revolutionize treatments for millions globally suffering from metabolic diseases. The company has garnered recognition through various achievements, including being chosen as a part of the Top 500 Global Deep tech Startups for 2019 by Hello Tomorrow and securing the Leading Innovators in Metabolic Condition Therapeutics 2019 accolade at the 4th Annual Healthcare & Pharmaceutical Awards by Global Health & Pharma (GHP) magazine. Additionally, they have been through respected accelerators such as the Plug and Play accelerator in Silicon Valley, RebelBio biotech accelerator in Ireland/UK, and the Growth Train food accelerator in Denmark. Having received a Seed Round investment in May 2017 from SOSV and RebelBio, Phyteau, Inc. is poised to make a significant impact in the biotechnology, health care, and pharmaceutical industries. Their groundbreaking research and development indicate a promising future for the company as they work towards providing solutions for individuals grappling with metabolic conditions globally.